Relationships between critical period of estrogen exposure and circulating levels of insulin-like growth factor-I (IGF-I) in breast cancer: Evidence from a case-control study

International Journal of Cancer

Volumn 126, Issue 2, 2010, Pages 508-514

  Wu, Mei Hsuan ^a   Chou, Yu Ching ^a   Chou, Wan Yun ^b   Hsu, Giu Cheng ^c   Chu, Chi Hong ^c   Yu, Cheng Ping ^c   Yu, Jyh Cherng ^c   Sun, Chien An ^a,b  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^c TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

Breast cancer; Case control study; Estrogen exposure; IGF I; IGFBP 3

Indexed keywords

BIOLOGICAL MARKER; ESTROGEN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADULT; AGED; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; BREAST CANCER; BREAST CARCINOGENESIS; CANCER RISK; CONTROLLED STUDY; FEMALE; HOSPITAL ADMISSION; HUMAN; HUMAN TISSUE; IMMUNORADIOMETRIC ASSAY; MAJOR CLINICAL STUDY; MEDICAL EXAMINATION; MENARCHE; POSTMENOPAUSE; PREGNANCY; PREMENOPAUSE; PRIORITY JOURNAL; QUESTIONNAIRE; RISK REDUCTION;

ADOLESCENT; ADULT; AGE FACTORS; AGED; BREAST NEOPLASMS; CASE-CONTROL STUDIES; ESTROGENS; FEMALE; HUMANS; IMMUNORADIOMETRIC ASSAY; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; LOGISTIC MODELS; MENARCHE; MIDDLE AGED; ODDS RATIO; PREGNANCY; RISK FACTORS; TAIWAN;

EID: 73549118559     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24722     Document Type: Article

References (52)

1. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004;4:579-91.
2. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer 2004;4:505-18.
3. Hursting SD, Nunez NP, Varticovski L, Vinson C. 2007 The obesity-cancer link: lessons learned from a fatless mouse. Cancer Res 2007;67:2391-3.
4. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 2004;363:1346-53.
5. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995:16:3-34.
6. Baxter RC. Insulin-like growth factor (IGF) binding proteins: interactions with IGFs and intrinsic bioactivities. Am J Physiol Endocrinol Metab 2000;278:E967-76.
7. Sugumar A, Liu YC, Xia Q, Koh YS, Matsuo K. Insulin-like growth factor (IGF)-I and IGF-binding protein 3 and the risk of premenopausal breast cancer: a meta-analysis of literature. Int J Cancer 2004;111:293-7.
8. Shi R, Yu H, McLarty J, Glass J. IGF-I and breast cancer: a meta-analysis. Int J Cancer 2004;111:418-23.
9. Renehan AG, Egger M, Minder C, O'Dwyer ST, Shalet SM, Zwahlen M. IGF-I, IGF-binding protein 3 and breast cancer risk: comparison of 3 meta-analyses. Int J cancer 2005;115:1006-7.
10. Fletcher O, Gibson L, Johnson N, Altmann DR, Holly JM, Ashworth A, Peto J, Silva Idos S. Polymorphisms and circulating levels in the insulin-like growth factor system and risk of breast cancer: a systematic review. Cancer Epidemiol Biomarkers Prev 2005;14:2-19.
11. Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med 2006;354:270-82.
12. Yee D, Lee AV. Crosstalk between the insulin-like growth factors and estrogens in breast cancer. J Mammary Gland Biol Neoplasia 2000; 5:107-15.
13. Stewart A, Westley B, May F. Modulation of the proliferative response of breast cancer cells to growth factors by estrogen. Br J Cancer 1992;66:640-8.
14. Ruan W, Catanese V, Wieczorek R, Feldman M, Kleinberg DL. Estradiol enhances the stimulatory effect of insulin-like growth factor-I (IGF-I) on mammary development and growth hormone-induced IGF-I messenger ribonucleic acid. Endocrinology 1995;136:1296-1302.
15. Kleinman D, Karas M, Roberts CT, LeRoith D, Phillip M, Segev Y, Levy J, Sharoni Y. Modulation of insulin-like growth factor I (IGF-I) receptors and membrane-associated IGF-binding proteins in endometrial cancer cells by estradiol. Endocrinology 1995:136:2531-7.
16. Chou YC, Wu MH, Yu JC, Lee MS, Yang T, Shih HL, Wu TY, Sun CA. Genetic polymorphisms of the methylenetetrahydrofolate reductase gene, plasma folate levels, and breast cancer susceptibility: a case-control study in Taiwan. Carcinogenesis 2006;27:2295-300.
17. Colditz GA, Frazier AL. Models of breast cancer show that risk is set by events of early life:prevention efforts must shift focus. Cancer Epidemiol Biomarkers Prev 1995;4:567-71.
18. Wu MH, Chou YC, Yu JC, Yu CP, Wu CC, Chu CM, Yang T, Lai CH, Hsieh CY, You SL, Chen CJ, Sun CA. Hormonal and body size factors in relation to breast cancer risk: a prospective study of 11,889 women in a low-incidence area. Ann Epidemiol 2006:16:223-9.
19. Kleinbaum DG, Kupper LL, Muller KE. Applied regression analysis and other multivariate methods. Boston: PWS-KENT, 1998.
20. Lee AV, Cui X, Oesterreich S. Cross-talk among estrogen receptor, epidermal growth factor, and insulin-like growth factor signaling in breast cancer. Clin Cancer Res 2001;7(12 Suppl):4429s.
21. Dupont J, LeRoith D. Insulin-like growth factor I and estradiol promote cell proliferation of MCF-7 breast cancer cells: new insights into their synergistic effects. Mol Pathol 2001;54:149-54.
22. Bruning PF, van Doorn J, Bonfrer JM, van Noord PA, Korse CM, Linders TC, Hart AA. Insulin-like growth-factor-binding protein 3 is decreased in early-stage operable pre-menopausal breast cancer. Int J Cancer 1995;62:266-70.
23. Hankinson SE, Willett WC, Coliditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE, Pollak M. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998;351:1393-6.
24. Toniolo P, Bruning PF, Akhmedkhanov A. Serum insulin-like growth factor-I and breast cancer. Int J Cancer 2000;88:828-32.
25. Yu H, Jin F, Shu XO, Li BD, Dai Q, Cheng JR, Berkel HJ, Zheng W. Insulin-like growth factors and breast cancer risk in Chinese women. Cancer Epidemiol Biomarkers Prev 2002;11:705-12.
26. Muti P, Quattrin T, Grant BJ, Krogh V, Micheli A, Schünemann HJ, Ram M, Freudenheim JL, Sieri S, Trevisan M, Berrino F. Fasting glucose is a risk factor for breast cancer: A prospective study. Cancer Epidemiol Biomarkers Prev 2002;11:1361-8.
27. Schernhammer ES, Holly JM, Pollak MN, Hankinson SE. Circulating levels of insulin-like growth factors, their binding proteins, and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2005;14:699-704.
28. Del Giudice ME, Fantus IG, Ezzat S, Mckeown-Eyssen G, Page D, Goodwin PJ. Insulin and related factors in premenopausal breast cancer risk. Breast Cancer Res Treat 1998;47:111-20.
29. Ng EH, Ji CY, Tan PH, Lin V, Soo KC, Lee KO. Altered serum levels of insulin-like growth-factor binding proteins in breast cancer patients. Ann Surg Oncol 1998;5:194-201.
30. Petridou E, Papadiamantis Y, Markopoulos C, Spanos E, Dessypris N, Trichopoulos D. Leptin and insulin growth factor I in relation to breast cancer. Cancer Causes Control 2000;11:383-8.
31. Li BD, Khosravi MJ, Berkel HJ, Diamandi A, Dayton MA, Smith M, Yu H. Free insulin-like growth factor-I and breast cancer risk. Int J Cancer 2001;91:736-9.
32. Kaaks R, Lundin E, Rinaldi S, Biessy C, Söderberg S, Lenner P, Janzon L, Riboli E, Berglund G, Hallmans G. Prospective study of IGF-I, IGF-binding proteins, and breast cancer risk, in Northern and Southern Sweden. Cancer Causes Control 2002;13:307-16.
33. Krajcik RA, Borofsky ND, Massardo S, Orentreich N. Insulin-like growth factor I (IGF-I), IGF-binding proteins, and breast cancer. Cancer Epidemiol Biomarkers Prev 2002;11:1566-73.
34. Keinan-Boker L, Bueno de Mesquita HB, Kaaks R, van Gils CH, van Noord PA, Rinaldi S, Riboli E, Seidell JC, Grobbee DE, Peeters PHM. Circulating levels of insulin-like growth factor I, its binding proteins -1, -2, -3, C-peptide and risk of postmenopausal breast cancer. Int J Cancer 2003;106:90-5.
35. Allen NE, Roddam AW, Allen DS, Fentiman IS, Dos Santos Silva I, Peto J, Holly JM, Key TJ. A prospective study of serum insulin-like growth factor-I (IGF-I), IGF-II, IGF-binding protein-3 and breast cancer risk. Br J Cancer 2005;92:1283-7.
36. Rinaldi S, Peeters PH, Berrino F, Dossus L, Biessy C, Olsen A, Tjonneland A, Overvad K, Clavel-Chapelon F, Boutron- Ruault MC, Téhard B, Nagel G, et al. IGF-I, IGFBP-3 and breast cancer risk in women: The European Proepective Investigation into Cancer and Nutrition (EPIC). Endocr Relat Cancer 2006;13:593-605.
37. Vatten LJ, Holly JM, Gunnell D, Tretli S. Nested case-control study of the association of circulating levels of serum insulin-like growth factor I and insulin-like growth factor binding protein 3 with breast cancer in young women in Norway. Cancer Epidemiol Biomarkers Prev 2008;17:2097-100.
38. Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Rohan TE, Manson JE, Li J, Ho GY, Xue X, Anderson GL, Kaplan RC, Harris TG, et al. Insulin, insulin-like growth factor-I, and risk of breast cancer in premenopausal women. J Natl Cancer Inst 2009;101:48-60.
39. Sachdev D, Yee D. The IGF system and breast cancer. Endocr Relat Cancer 2001;8:197-209.
40. de Leon DD, Wilson DM, Powers M, Rosenfeld RG. Effects of insulin-like growth factors (IGFs) and IGF receptor antibodies on the proliferation of human breast cancer cells. Growth Factors 1992;6:327-36.
41. Peyrat JP, Bonneterre J, Hecquet B, Vennin P, Louchez MM, Fournier C, Lefebvre J, Demaille A. Plasma insulin-like growth factor-I (IGF-I) concentrations in human breast cancer. Eur J Cancer 1993;29A:492-7.
42. Pollak MN. Endocrine effects of IGF-I on normal and transformed breast epithelial cells: potential relevance to strategies for breast cancer treatment and prevention. Breast Cancer Res Treat 1998;47: 209-17.
43. Kleinberg DL. Role of IGF-I in normal mammary development. Breast Cancer Res Treat 1998;47:201-8.
44. Peyrat JP, Bonneterre J. Type I IGF receptor in human breast diseases. Breast Cancer Res Treat 1992;22:59-67.
45. Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocrine Rev 2002;23:824-54.
46. McCaig C, Perks CM, Holly JM. Intrinic actions of IGFBP-3 and IGFBP-5 on Hs578T breast cancer epithelial cells: inhibition or accentuation of attachment and survival is dependent upon the presence of fibronectin. J Cell Sci 2002;115:4293-303.
47. Stewart AJ, Johnson MD, May FE, Westley BR. Role of insulin-like growth factors and the type I IGF receptor in the estrogen-stimulated proliferation of human breast cancer cells. J Biol Chem 1990;178:21172-8.
48. Lukanova A, Zeleniuch-Jacquotte A, Lundin E, Micheli A, Arslan AA, Rinaldi S, Muti P, Lenner P, Koenig KL, Biessy C, Krogh V, Riboli E, et al. Prediagnostic levels of C-peptide, IGF-I, IGFBP-1, -2, -3 and risk of endometrial cancer. Int J Cancer 2004;108:262-8.
49. Kaaks R, Toniolo P, Akhmedkhanov A, Lukanova A, Biessy C, Dechaud H, Rinaldi S, Zeleniuch-Jacquotte A, Shore RE, Riboli E. Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins and colorectal cancer risk in women. J Natl Cancer Inst 2000; 92:1592-600.
50. Borofsky ND, Vogelman JH, Krajcik RA, Orentreich N. Utility of insulin-like growth factor-I as a biomarker in epidemiologic studies. Clin Chem 2002;48:2248-51.
51. Holmes MD, Pollak MN, Willett WC, Hankinson SE. Dietary correlates of plasma insulin-like growth factor I and insulin-like growth factor binding protein 3 concentrations. Cancer Epidemiol Biomarkers Prev 2002;11:852-61.
52. Chang S, Wu X, Yu H, Spitz MR. Plasma concentrations of insulin-like growth factors among healthy adult men and postmenopausal women: Associations with body composition, lifestyle, and reproductive factors. Cancer Epidemiol Biomarkers Prev 2002;11:758-66.